Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$54.79 USD
-1.66 (-2.94%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $55.20 +0.41 (0.75%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CORT 54.79 -1.66(-2.94%)
Will CORT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Other News for CORT
Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity
Corcept Therapeutics: Strong Financial Performance and Promising Clinical Trials Justify Buy Rating
Corcept Therapeutics price target raised to $73.50 from $72 at Ladenburg
Corcept Therapeutics price target raised by $1.50 at Ladenburg, here's why